G. O. Oludare, I. C. Orabueze, R. A. Lawal, E. O. Lawanson, O. E. Ifekwuna, Y. M. Agbaje, E. M. Adamu, P. E. Ajifowose.
Abstract
Antioxidant depletion and nitric oxide deficiency are consequences of L-NG-Nitro Arginine Methyl Ester (L- NAME) induced hypertension. This study assessed the role of D-ribose-L-cysteine (DRLC) a compound that enhances the production of intracellular glutathione in pregnant rats administered L-NAME. Twenty-four pregnant rats were randomly assigned into 4 groups of control, L-NAME, L-NAME + DRLC and the DRLC group. Both L-NAME (50 mg/kg subcutaneously) and DRLC (200 mg/kg orally) were administered from days 12-19 of pregnancy. Blood pressure, oxidative stress indices, liver enzymes, albumin, total protein, c-reactive protein and nitric oxide levels were measured on day 20 of pregnancy. The results showed that L-NAME + DRLC reduced blood pressure induced by L-NAME during pregnancy. L-NAME + DRLC rats reversed the decreased placental and foetal weights observed in the L-NAME group. DRLC also reverses lipid peroxidation and increased the antioxidant levels in the placenta. The increased CRP levels in the L-NAME group were reduced in the L-NAME + DRLC group while the reduced nitric oxide level in the L-NAME group was significantly increased in the L-NAME + DRLC group. We conclude that DRLC reduced blood pressure by ameliorating the effects of oxidative stress and inflammation in L-NAME-induced pregnancy hypertension.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!